Abstract
Autoimmune processes in general take many years before their clinical manifestation as a disease becomes apparent and T1D is no exception, sometimes taking up to a decade, or more for clinical presentation. This asymptomatic period offers a great window of opportunity for the prediction and prevention of full-blown disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akashi T, Nagafuchi S et al (1997) Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in non-diabetic mice. Int Immunol 9:1159–1164
Atkinson MA, Bluestone JA et al (2011) How does Type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes 60(5):1370–1379
Baekkeskov S, Aanstoot HJ et al (1990) Identification of the 64 K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347(6289):151–156
Borges CR, Rehder DS et al (2010) Full-length characterization of proteins in human populations. Clin Chem 56(2):202–211
Carey C, Purohit S et al (2010) Advances and challenges in biomarker development for type 1 diabetes prediction and prevention using ‘omic’ technologies. Expert Opin Med Diagn 4(5):397–410
Cassiday L (2008) Candidate biomarkers for type 1 diabetes. J Proteome Res 7(2):482
Eisenbarth G (1986) Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314(21):1360–1368
Haskins K, McDuffie M (1990) Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 249(4975):1433–1436
Hawa MI, Fava D et al (2000) Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care 23(2):228–233
Lennon GP, Bettini M et al (2009) T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 31(4):643–653
Leslie D, Lipsky P et al (2001) Autoantibodies as predictors of disease. J Clin Invest 108(10):1417–1422
Lyons PA, Wicker LS (1999) Localising quantitative trait loci in the NOD mouse model of type 1 diabetes. Curr Dir Autoimmun 1:208–225
Moser M (2003) Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity 19:5–8
Nakayama M, Abiru N et al (2005) Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435(7039):220–223
Notkins AL, Lernmark A (2001) Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 108(9):1247–1252
Ounissi-Benkalha H, Polychronakos C (2008) The molecular genetics of type 1 diabetes: new genes and emerging mechanisms. Trends Mol Med 14(6):268–275
Palmer JP, Asplin CM et al (1983) Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222(4630):1337–1339
Rabin DU, Pleasic SM et al (1994) Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 152(6):3183–3188
Rubio-Cabezas O, Minton JAL et al (2009) Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care 32(1):111–116
Ryden A, Stechova K et al (2009) Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes. Diabetes Metab Res Rev 25(4):335–343
Sebzda E, Mariathasan S et al (1999) Selection of the T cell repertoire. Annu Rev Immunol 17(1):829–874
Srikanta S, Ganda OP et al (1985) First-degree relatives of patients with type I diabetes mellitus. islet-cell antibodies and abnormal insulin secretion. N Eng J Med 313(8):461–464
Turley S, Poirot L et al (2003) Physiological β cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 198(10):1527–1537
Turner R, Stratton I et al (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. The Lancet 350(9087):1288–1293
Verge CF, Stenger D et al (1998) Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 47(12):1857–1866
Verge CF, Gianani R et al (1996) Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45(7):926–933
Wasserfall CH, Atkinson MA (2006) Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun Rev 5(6):424–428
Wenzlau JM, Juhl K et al (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 104(43):17040–17045
Wong FS, Visintin I et al (1998) The role of lymphocyte subsets in accelerated diabetes in nonobese diabetic-rat insulin promoter–B7-1 (NOD-RIP-B7-1) mice. J Exp Med 187(12):1985–1993
Wong FS, Visintin I et al (1996) CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 183(1):67–76
Ziegler AG, Nepom GT (2010) Prediction and pathogenesis in type 1 diabetes. Immunity 32(4):468–478
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Copyright information
© 2016 The Author(s)
About this chapter
Cite this chapter
Singh, P. et al. (2016). Predictors and Pathogenesis of Type 1 Diabetes. In: Therapeutic Perspectives in Type-1 Diabetes. SpringerBriefs in Applied Sciences and Technology. Springer, Singapore. https://doi.org/10.1007/978-981-10-0602-9_3
Download citation
DOI: https://doi.org/10.1007/978-981-10-0602-9_3
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-0601-2
Online ISBN: 978-981-10-0602-9
eBook Packages: EngineeringEngineering (R0)